Targeted Inhibition of LPL/FABP4/CPT1 fatty acid metabolic axis can effectively prevent the progression of nonalcoholic steatohepatitis to liver cancer
Haoran Yang, Qingmei Deng, Tun Ni, Yu Liu, Li Lu, Haiming Dai, Hongzhi Wang, Wulin Yang
Abstract
These results suggest that activation of the LPL/FABP4/CPT1 axis is essential for LCSCs maintenance, which acts synergistically with a variety of up-regulated oncogenic signals that drive the hepatocyte-LCSCs transdifferentiation during NASH to HCC progression. Thus, targeting the LPL/FABP4/CPT1 axis may provide a potential direction for NASH-related HCC prevention.
Topics & Concepts
Nonalcoholic fatty liver diseaseCancer researchBiologyCancerFatty liverIn vivoSteatohepatitisInternal medicineDiseaseMedicineGeneticsCancer, Lipids, and MetabolismLiver Disease Diagnosis and TreatmentPeroxisome Proliferator-Activated Receptors